Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 23
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 23

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderBioXcel Therapeutics · 40
Strongest available pathOpko Health · -58.4%
Widest latest marginOpko Health · -37.2%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1BTAI · Nasdaq

BioXcel Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2017Branford, Connecticut$4.3M market cap
View full Companies Radar profile
40Cautious
Snapshot price$0.14as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.00BBioXcel Therapeutics, Inc.
Net margin-10887.4%FY2025
P/E snapshot-0.1xone ratio, not a verdict
Prism attention22.6%share across these five
Filing track recordRevenue, USD billions
+71.2%
$0$0.0B$0.0B$0.0BFY2022: $0.000BFY2023: $0.001BFY2024: $0.002BFY2025: $0.001B2022202320242025
FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 19.6%
52-week position0% through range
$0.12$4.29
News mentions837
Community mentions0partial coverage
U.S.-scope patents233
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal30/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LSTA · Nasdaq

Caladrius Biosciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1980New York City, New York$14.1M market cap
View full Companies Radar profile
40Cautious
Snapshot price$1.57as of page date
Monthly-close return-91.4%five-year window
FY2024 revenue$0.00BLISATA THERAPEUTICS, INC.
Net margin-9756.5%FY2024
P/E snapshot-1.4xone ratio, not a verdict
Prism attention11.3%share across these five
Filing track recordRevenue, USD billions
-98.8%
$0$0.0B$0.0B$0.0BFY2012: $0.014BFY2013: $0.015BFY2024: $0.000B201220132024
FY2012–FY2024 · 3 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2012, FY2013 · CAGR -89.1%
52-week position14% through range
$0.99$5.07
News mentions418
Community mentions0partial coverage
U.S.-scope patents12
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability90/100
Market position6/100
Capital-event signal49/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3SDEV · NYSE

NovaBay Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Emeryville$43.5M market cap
View full Companies Radar profile
40Cautious
Snapshot price$0.86as of page date
Monthly-close return-100.0%five-year window
FY2024 revenue$0.01BStablecoin Development Corp
Net margin-73.8%FY2024
Prism attention18.0%share across these five
Filing track recordRevenue, USD billions
-1.5%
$0$0.0B$0.0B$0.0BFY2020: $0.010BFY2021: $0.008BFY2022: $0.014BFY2023: $0.015BFY2024: $0.010B20202021202220232024
FY2020–FY2024 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.4%
52-week position0% through range
$0.85$99.75
News mentions665
Community mentions0partial coverage
U.S.-scope patents116
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal39/100
Management stability90/100
Market position17/100
Capital-event signal56/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 5 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 4 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4HIND · Nasdaq

Obalon

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Carlsbad$15.2M market cap
View full Companies Radar profile
40Cautious
Snapshot price$2.17as of page date
Monthly-close return-100.0%five-year window
FY2024 revenue$0.01BVyome Holdings, Inc
Net margin-89.1%FY2024
Prism attention6.1%share across these five
Filing track recordRevenue, USD billions
+404.2%
$0$0.0B$0.0B$0.0BFY2020: $0.002BFY2021: $0.014BFY2022: $0.011BFY2023: $0.009BFY2024: $0.008B20202021202220232024
FY2020–FY2024 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 49.8%
52-week position5% through range
$1.75$9.56
News mentions225
Community mentions25partial coverage
U.S.-scope patents225
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position11/100
Capital-event signal69/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5OPK · Nasdaq

Opko Health

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1991Miami, Florida$1.13B market cap
View full Companies Radar profile
39Cautious
Snapshot price$1.52as of page date
Monthly-close return-58.4%five-year window
FY2025 revenue$0.61BOPKO HEALTH, INC.
Net margin-37.2%FY2025
P/E snapshot-5.5xone ratio, not a verdict
Prism attention42.0%share across these five
Filing track recordRevenue, USD billions
-65.8%
$0$0.6B$1.2B$1.8BFY2021: $1.775BFY2022: $1.004BFY2023: $0.863BFY2024: $0.713BFY2025: $0.607B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -23.5%
52-week position72% through range
$0.98$1.73
News mentions1.6K
Community mentions206partial coverage
U.S.-scope patents210
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal24/100
Management stability90/100
Market position33/100
Capital-event signal47/100
Innovation pulse8/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 23 M&A involvements, 12 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Opko Health
-58.4%
Caladrius Biosciences
-91.4%
BioXcel Therapeutics
-100.0%
NovaBay Pharmaceuticals
-100.0%
Obalon
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Opko Health
$0.61B
NovaBay Pharmaceuticals
$0.01B
Obalon
$0.01B
BioXcel Therapeutics
$0.00B
Caladrius Biosciences
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Opko Health
-37.2%
NovaBay Pharmaceuticals
-73.8%
Obalon
-89.1%
Caladrius Biosciences
-9756.5%
BioXcel Therapeutics
-10887.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Opko Health
42.0%
BioXcel Therapeutics
22.6%
NovaBay Pharmaceuticals
18.0%
Caladrius Biosciences
11.3%
Obalon
6.1%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Opko Health leads the conversation

It holds 42.0% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.61B.

Price path

Opko Health leads the available price paths

Its monthly-close return is -58.4% for the five-year window. At the other end, NovaBay Pharmaceuticals is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Opko Health has the widest latest margin

Its FY2025 net margin is -37.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Opko Health shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -5.5x while its five-year window price return is -58.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · BTAI

BioXcel Therapeutics

837available Prism news records

Prism top themes

Price action & investor response
41
Legal, arbitration & regulatory
30
Earnings & financial performance
16
Capital allocation & transactions
10
Leadership & governance
6

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+123.0%194 latest 12m vs 87 prior 12m
2023-12: 0 mentions2024-01: 1 mentions2024-02: 39 mentions2024-03: 23 mentions2024-04: 8 mentions2024-05: 13 mentions2024-06: 5 mentions2024-07: 4 mentions2024-08: 4 mentions2024-09: 6 mentions2024-10: 8 mentions2024-11: 7 mentions2024-12: 4 mentions2025-01: 2 mentions2025-02: 11 mentions2025-03: 17 mentions2025-04: 13 mentions2025-05: 6 mentions2025-06: 4 mentions2025-07: 5 mentions2025-08: 36 mentions2025-09: 28 mentions2025-10: 11 mentions2025-11: 7 mentions2025-12: 4 mentions2026-01: 20 mentions2026-02: 10 mentions2026-03: 21 mentions2026-04: 32 mentions2026-05: 16 mentions2023-122026-05

Machine-classified coverage tone

96.2% positive+3.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

ssri effectiveness trials 25treatment-resistant depression studies 19mood stabilizer toxicity 18drug repurposing ai 17stock price 14stock performance 12ssri discontinuation syndrome 12antidepressant response rates 12

Keyword tag occurrences in available Prism news records.

Coverage: 2014-10-08–2026-05-16 · trend and themes shown through 2026-05
Areas of research · OPK

Opko Health

1,551available Prism news records

Prism top themes

Earnings & financial performance
49
Price action & investor response
47
Legal, arbitration & regulatory
23
Capital allocation & transactions
19
Leadership & governance
18

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+6.8%188 latest 12m vs 176 prior 12m
2024-01: 27 mentions2024-02: 24 mentions2024-03: 34 mentions2024-04: 18 mentions2024-05: 22 mentions2024-06: 5 mentions2024-07: 20 mentions2024-08: 10 mentions2024-09: 10 mentions2024-10: 7 mentions2024-11: 6 mentions2024-12: 10 mentions2025-01: 10 mentions2025-02: 33 mentions2025-03: 27 mentions2025-04: 25 mentions2025-05: 9 mentions2025-06: 9 mentions2025-07: 8 mentions2025-08: 13 mentions2025-09: 13 mentions2025-10: 19 mentions2025-11: 19 mentions2025-12: 6 mentions2026-01: 10 mentions2026-02: 39 mentions2026-03: 20 mentions2026-04: 30 mentions2026-05: 7 mentions2026-06: 4 mentions2024-012026-06

Machine-classified coverage tone

96.6% positive+6.2 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 10earnings report 6investigational new vaccine 5startup valuation 4stock performance 4innovative product 4investor call 4annual earnings 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-11–2026-06-18 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

OPK

Opko Health

206 mentions
Stock and valuation
92
Products, pricing and logistics
10
Other company context
1
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 206 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

BTAI

BioXcel Therapeutics

through 2026-01-13
Earnings releases 8Lawsuits 7Listing / IPO 2Regulatory 2Company announcements 1
  1. Earnings releases

    Based on Bioxcel Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $98 thousand and a GAAP net loss of $30.91 million.

  2. Regulatory

    On September 17, 2025, Nasdaq delivered a notice to the Company confirming it had regained compliance with the MVLS Rule.

  3. Listing / IPO

    Bioxcel Therapeutics Inc., of Branford, Conn., priced its IPO of about 5.4 million shares at $11 each, the low end of its previously proposed range, for gross proceeds of about $60 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LSTA

Caladrius Biosciences

through 2025-02-14
Listing / IPO 1
  1. Listing / IPO

    Concurrently, Caladrius said Aspire Capital Fund LLC agreed to acquire 847,458 common shares, also at $4.72 apiece, in a registered direct offering of $4 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SDEV

NovaBay Pharmaceuticals

through 2025-10-21
Earnings releases 15Asset acquisitions 5Company announcements 5M&A 4Regulatory 4
  1. Company announcements

    NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards.

  2. Regulatory

    The NYSE American formally notified NovaBay in a letter dated October 20, 2025, confirming that the Company had successfully addressed and resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.

  3. M&A

    sale of its Avenova brand and related assets to Physician Recommended Nutriceuticals in January.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

HIND

Obalon

through 2026-09-01
Earnings releases 11Leadership changes 7Funding Rounds 6Listing / IPO 4M&A 4
  1. Earnings releases

    Prism's available event log records 11 earnings releases for Obalon.

  2. Leadership changes

    Prism's available event log records 7 leadership changes for Obalon.

  3. Funding Rounds

    Prism's available event log records 6 funding rounds for Obalon.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

OPK

Opko Health

through 2025-11-03
Earnings releases 17M&A 9Asset acquisitions 7Leadership changes 2Business contracts 1
  1. Earnings releases

    Following the latest downgrade, the current consensus, from the six analysts covering OPKO Health, is for revenues of US$570m in 2026, which would reflect a definite 11% reduction in OPKO Health's sales over the past 12 months.

  2. Company announcements

    The firm announced that its revenues declined nearly 13 percent to $151.7 million in the quarter, missing the consensus Wall Street estimate due to lower revenues from services.

  3. Business contracts

    Our e-commerce partnership and exclusive distribution agreement with OPKO Health, Inc. ("OPKO") for the sale of its health, nutrition, and dietary supplements to customers in China continues to grow, supported by recent approval for higher volumes of product imports which previously limited sales.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 111–118. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Opko Health and Opko Health

Opko Health has the largest displayed latest revenue at $0.61B; Opko Health has the widest displayed latest margin at -37.2%.

Open Opko Health in Companies Radar
Comparisons
Anomalies

Opko Health has the widest attention-readiness rank gap

It ranks #1 by measured news attention (42.0%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Opko Health in Companies Radar

Obalon shows a price-operating divergence to inspect

Its displayed filing-revenue change is +404.2% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Obalon in Companies Radar
Explanations

Attention measures coverage volume, not quality

Opko Health's 42.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Opko Health in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open BioXcel Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 40/100 score.

Open BioXcel Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon